When was Molcure founded?

Molcure was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Molcure located?

Molcure is headquartered in Tokyo, Japan.

Who is the current CEO of Molcure?

Ryu Ogawa of Molcure. They have also founded 1 company.

How many employees does Molcure have?

As of Aug 31, 2026, the latest employee count at Molcure is 21.

Is Molcure a funded company?

Molcure is a funded company, having raised a total of $11.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 31, 2013.

When was the latest funding round of Molcure?

Molcure's latest funding was a $***** Series C round on Aug 18, 2021, with participation from 6 investors.

Where does Molcure rank among its competitors?

Molcure ranks 11th amongst 414 active competitors, of which 87 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was OutSee, which secured $3.36M in Jan, 2026.

Who are the top competitors of Molcure?

Molcure's top competitors include Deep Genomics, Hexagon Bio and Envisagenics. Among them, OutSee secured the most recent funding round in January, 2026.

Molcure - 2026 Company Profile, Team, Funding & Competitors

Molcure is a series C company based in Tokyo (Japan), founded in 2013 by Yoichiro Hara, Ryu Ogawa and Yutaro Kyono. It operates as a Provider of AI-based platform for drug discovery and design. Molcure has raised $11.7M in funding from investors like JAFCO Group, Dai-Ichi Life and GMO Venture Partners. The company has 414 active competitors, including 87 funded and 38 that have exited. Its top competitors include companies like Deep Genomics, Hexagon Bio and Envisagenics.

Company Details

Provider of AI-based platform for drug discovery and design. The company uses Next Generation Sequencing and Molecular Biology technology for the discovery and detection of antibody molecules.

Website: molcure.com
Social

Key Metrics

Founded Year

2013

Location

Tokyo, Japan

Stage

Series C

Total Funding

$11.7M in 5 rounds

Latest Funding Round

Series C, Aug 18, 2021, $*****

Investors

JAFCO Group & 8 more

Ranked

11^th among 414 active competitors

Employee Count

21 as on Aug 31, 2026

Similar Companies

OpenEvidence & 3415 more

View Molcure's full profile

Molcure has raised a total funding of $11.7M over 5 rounds. Its first funding round was on Jul 31, 2013. Its latest funding round was a Series C round on Aug 18, 2021 for $*****. 6 investors participated in its latest round. Molcure has 9 institutional investors.

Here is the list of recent funding rounds of Molcure:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 18, 2021	6555422	Series C	6103962	4747451	8137581	5698671
Dec 03, 2018	5248470	Series B	3812779	5818702	7363695	5272271
2016	4805	Grant (prize money)	9776	7437	2359	Chivas Venture

Access funding benchmarks and valuations. Sign up today!

View details of Molcure's funding rounds and investors

The founders of Molcure are Yoichiro Hara, Ryu Ogawa and Yutaro Kyono. Ryu Ogawa is the CEO of Molcure.

Here are the details of Molcure's key team members:

Yoichiro Hara: Co-Founder & COO of Molcure and founder of 1 other company.
Contact Info: 2 email addresses
Ryu Ogawa: Co-Founder & CEO of Molcure.
Yutaro Kyono: Co-Founder & CTO of Molcure.
Contact Info: 1 email address

View details of Molcure's Founder profiles and Board Members

Molcure's employee count trend

Molcure has 21 employees as of Aug 26. Here is Molcure's employee count trend over the years:

Uncover Molcure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Molcure include Deep Genomics, Hexagon Bio and Envisagenics. Here is the list of Top 10 competitors of Molcure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
2nd	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Two Sigma Ventures & 10 others	62/100
3rd	Envisagenics 2014, Long Island City (United States), Series B	AI-driven biotechnology company that focuses on the discovery and development of novel RNA splicing therapeutics	$46.8M	Red Cell Partners, Bristol-Myers Squibb & 17 others	61/100
4th	Phoremost 2015, Cambridge (United Kingdom), Series B	Developer of a phenotypic screening platform for drug target discovery	$76.8M	Parkwalk, Amadeus Capital & 14 others	59/100
5th	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Jolt Capital, Debiopharm & 6 others	58/100
6th	Biological Dynamics 2010, San Diego (United States), Series C	Provider of molecular diagnostics plaform	$67.6M	Alexandria, Heritage Group & 6 others	58/100
7th	Broken String Biosciences 2020, Cambridge (United Kingdom), Series A	Developer of biopharmaceutical products & cell therapies by using genome sequencing data	$15M	Illumina Ventures, Illumina & 14 others	55/100
8th	54gene 2019, Lagos (Nigeria), Deadpooled	Provider of gene biobanking database and services for research purposes	$45M	Better Ventures, Fifty Years & 20 others	54/100
9th	OutSee United Kingdom, Seed	Developer of an artificial intelligence engine for predictive genomics	$5.79M	Ahren, Panacea Venture & 2 others	54/100
10th	Zetta Genomics 2018, Worcester (United Kingdom), Seed	Provider of genomic data analysis software for clinical labs & research organizations	$10.4M	Nina Capital, APEX Ventures & 12 others	54/100
11th	Molcure 2013, Tokyo (Japan), Series C	Provider of AI-based platform for drug discovery and design	$11.7M	Dai-Ichi Life, STRIVE & 7 others	53/100